Biology-inspired microphysiological systems to advance medicines for patient benefit and animal welfare

Abstract

The first microfluidic microphysiological systems (MPS) entered the academic scene more than 15 years ago and were considered an enabling technology to human (patho)biology in vitro and, therefore, provide alternative approaches to laboratory animals in pharmaceutical drug development and academic research. Nowadays, the field generates more than a thousand scientific publications per year. Despite the MPS hype in academia and by platform providers, which says this technology is about to reshape the entire in vitro culture landscape in basic and applied research, MPS approaches have neither been widely adopted by the pharmaceutical industry yet nor reached regulated drug authorization processes at all. Here, 46 leading experts from all stakeholders - academia, MPS supplier industry, pharmaceutical and consumer products industries, and leading regulatory agencies - worldwide have analyzed existing challenges and hurdles along the MPS-based assay life cycle in a second workshop of this kind in June 2019. They identified that the level of qualification of MPS-based assays for a given context of use and a communication gap between stakeholders are the major challenges for industrial adoption by end-users. Finally, a regulatory acceptance dilemma exists against that background. This t4 report elaborates on these findings in detail and summarizes solutions how to overcome the roadblocks. It provides recommendations and a roadmap towards regulatory accepted MPS-based models and assays for patients' benefit and further laboratory animal reduction in drug development. Finally, experts highlighted the potential of MPS-based human disease models to feedback into laboratory animal replacement in basic life science research.

References 91

1. 1.
   Merging organoid and organ-on-a-chip technology to generate complex multi-layer tissue models in a human retina-on-a-chip platform · 2019

   No notice
2. 2.

   Ainslie GR, David M, Ewart L (2019 ). Microphysiological lung models to evaluate the safety of new pharmaceutical modalities: A biopharmaceutical perspective. Lab Chip 19, 3152–3161

   Not in our library10.1039/c9lc00492k

3. 3.
   A Tissue Engineered Blood Vessel Model of Hutchinson-Gilford Progeria Syndrome Using Human iPSC-derived Smooth Muscle Cells · 2017

   Not checked
4. 4.

   Baker M, (2011 ). Tissue models. A living system on a chip. Nature 471, 661–665

   Not in our library10.1038/471661a

5. 5.

   Balls M, Blaauboer B, Brusick D (1990 ). Report and recommendations of the CAAT/ERGATT workshop on the validation of toxicity test procedures. Altern Lab Anim 18, 313–337.

   Not in our library

6. 6.

   Barrile R, van der Meer AD, Park H (2018 ). Organ-on-chip recapitulates thrombosis induced by an anti-CD154 monoclonal antibody: Translational potential of advanced microengineered systems. Clin Pharmacol Ther 104, 1240–1248

   Not in our library10.1002/cpt.1054

7. 7.
   Functional coupling of human pancreatic islets and liver spheroids on-a-chip: Towards a novel human ex vivo type 2 diabetes model · 2017

   Corrected
8. 8.
   Development of a Gut-on-a-Chip Model for High Throughput Disease Modeling and Drug Discovery · 2019

   No notice
9. 9.

   Beilmann M, Boonen H, Czich A (2019 ). Optimizing drug discovery by investigative toxicology: Current and future trends. ALTEX 36, 289–313

   Not in our library10.14573/altex.1808181

10. 10.

    Benam KH, Novak R, Nawroth J (2016a ). Matched-comparative modeling of normal and diseased human airway responses using a microengineered breathing lung chip. Cell Syst 3, 456–466

    Not in our library10.1016/j.cels.2016.10.003

11. 11.

    Benam KH, Villenave R, Lucchesi C (2016b ). Small airway-on-a-chip enables analysis of human lung inflammation and drug responses in vitro. Nat Methods 13, 151–157

    Not in our library10.1038/nmeth.3697

12. 12.

    Chou DB, Frismantas V, Milton Y (2018 ). Human bone marrow disorders recapitulated in vitro using organ chip technology. bioRxiv, preprint

    Not in our library10.1101/458935

13. 13.

    Costa PF, Albers HJ, Linssen JE (2017 ). Mimicking arterial thrombosis in a 3D-printed microfluidic in vitro vascular model based on computed tomography angiography data. Lab Chip 17, 2785–2792

    Not in our library10.1039/c7lc00202e

14. 14.

    Desprez B, Dent M, Keller D (2018 ). A strategy for systemic toxicity assessment based on non-animal approaches: The cosmetics Europe long range science strategy programme. Toxicol In Vitro 50, 137–146

    Not in our library10.1016/j.tiv.2018.02.017

15. 15.

    de Graaf MNS, Cochrane A, van den Hil FE (2019 ). Scalable microphysiological system to model three-dimensional blood vessels. APL Bioeng 3, 026105.

    Not in our library10.1063/1.5090986

16. 16.

    EC (2009 ). Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products. OJ L 342, 59–209. https://bit.ly/2XhN5yU (accessed 12.11.2019).

    Not in our library

17. 17.

    EURL ECVAM – European Reference Laboratory for alternatives to animal testing (2018 ). ECVAM 2018 Survey. https://bit.ly/2wkcsoB (accessed 12.11.2019).

    Not in our library

18. 18.
    Interconnected Microphysiological Systems for Quantitative Biology and Pharmacology Studies · 2018

    No notice
19. 19.

    EMA - European Medicines Agency (2006 ). General Principles Processing Joint FDA EMEA Voluntary Genomic Data Submissions (VGDSs) with the framework of the Confidentiality Arrangement. https://bit.ly/2JMX6fw (accessed 12.11.2019).

    Not in our library

20. 20.

    EMA (2013 ). ICH M3 (R2) Non-Clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals. https://bit.ly/39MimfW (accessed 12.11.2019).

    Not in our library

21. 21.

    EMA (2016 ). Guideline on the Principles of Regulatory Acceptance of 3Rs (Replacement, Reduction, Refinement) Testing Approaches. https://bit.ly/2wnDStK (accessed 12.11.2019).

    Not in our library

22. 22.

    EMA (2017 ). First EMA Workshop on Non-animal Approaches in Support of Medicinal Product Development: Challenges and Opportunities for Use of Micro-physiological Systems. https://bit.ly/2JJpKOt (accessed 12.11.2019).

    Not in our library

23. 23.

    Emulate, Inc. (2017 ). FDA Signs Collaborative Agreement with Emulate, Inc. to Use Organs-on-Chips Technology as a Toxicology Testing Platform for Understanding How Products Affect Human Health and Safety Emulate, Inc. press release, 4 11, 2017. https://emulatebio.com/press/fda-collab-agreement-emulate/ (accessed 12.11.2019).

    Not in our library

24. 24.

    EPA - United States Environmental Protection Agency (2018 ). Strategic Plan to Promote the Development and Implementation of Alternative Test Methods Within the TSCA Program EPA Document# EPA-740-R1–8004, 6 22, 2018, Office of Chemical Safety and Pollution Prevention https://www.epa.gov/sites/production/files/2018-06/documents/epa_alt_strat_plan_6-20-18_clean_final.pdf (accessed 12.11.2019).

    Not in our library

25. 25.

    EPA (2019 ). Directive to Prioritize Efforts to Reduce Animal Testing. Memorandum, 9 10, 2019. https://www.epa.gov/sites/production/files/2019-09/documents/image2019-09-09-231249.pdf (accessed 12.11.2019).

    Not in our library

26. 26.

    Ewart L, Fabre K, Chakilam A (2017 ). Navigating tissue chips from development to dissemination: A pharmaceutical industry perspective. Exp Biol Med (Maywood) 242, 1579–1585

    Not in our library10.1177/1535370217715441

27. 27.

    Fitzpatrick S (2017 ). Determining the Predictive Ability of In Vitro Microphysiological Systems to Answer Critical Regulatory Questions. US Food and Drug Administration EMA Workshop, 10 5, 2017. https://bit.ly/34iFQbu (accessed 12.11.2019).

    Not in our library

28. 28.

    Fogel DB (2018 ). Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review. Contemp Clin Trials Commun 11, 156–164

    Not in our library10.1016/j.conctc.2018.08.001

29. 29.

    Foster AJ, Chouhan B, Regan SL (2019 ). Integrated in vitro models for hepatic safety and metabolism: Evaluation of a human liver-chip and liver spheroid. Arch Toxicol 93, 1021–1037

    Not in our library10.1007/s00204-019-02427-4

30. 30.

    Franzen N, van Harten WM, Retel VP (2019 ). Impact of organ-on-a-chip technology on pharmaceutical R&D costs. Drug Discov Today 24, 1720–1724

    Not in our library10.1016/j.drudis.2019.06.003

31. 31.

    Gaio N, van Meer B, Quirós Solano W (2016 ). Cytostretch, an organ-on-chip platform. Micromachines 7, 120

    Not in our library10.3390/mi7070120

32. 32.

    Glieberman AL, Pope BD, Zimmerman JF (2019 ). Synchronized stimulation and continuous insulin sensing in a microfluidic human islet on a chip designed for scalable manufacturing. Lab Chip 19, 2993–3010

    Not in our library10.1039/c9lc00253g

33. 33.

    Hackett JL and Lesko LJ (2003 ). Microarray data - The US FDA, industry and academia. Nat Biotechnol 21, 742–743

    Not in our library10.1038/nbt0703-742

34. 34.

    Halaidych OV, van den Hil F, Mummery CL (2018a ). Microfluidic assay for the assessment of leukocyte adhesion to human induced pluripotent stem cell-derived endothelial cells (hiPSC-ECs). J Vis Exp 141, e58678

    Not in our library10.3791/58678

35. 35.

    Halaidych OV, Freund C, van den Hil F (2018b ). Inflammatory responses and barrier function of endothelial cells derived from human induced pluripotent stem cells. Stem Cell Reports 10, 1642–1656

    Not in our library10.1016/j.stemcr.2018.03.012

36. 36.

    Hardwick RN, Betts CJ, Whritenour J (2019 ). Drug-induced skin toxicity: Gaps in preclinical testing cascade as opportunities for complex in vitro models and assays. Lab Chip 20, 199–214

    Not in our library10.1039/c9lc00519f

37. 37.

    Hartung T, Bremer S, Casati S (2004 ). A modular approach to the ECVAM principles on test validity. Altern Lab Anim 32, 467–472

    Not in our library10.1177/026119290403200503

38. 38.

    Hartung T (2007 ). Food for thought … on validation. ALTEX 24, 67–73

    Not in our library10.14573/altex.2007.2.67

39. 39.

    Hartung T, Hoffmann S and Stephens M (2013 ). Mechanistic validation. ALTEX 30, 119–130

    Not in our library10.14573/altex.2013.2.119

40. 40.

    Hartung T, De Vries R, Hoffmann S (2019 ). Toward good in vitro reporting standards. ALTEX 36, 3–17

    Not in our library10.14573/altex.1812191

41. 41.

    Herland A, Maoz BM, Debarun D (2020 ). Quantitative prediction of human drug pharmacokinetic responses using multiple vascularized organ chips coupled by fluid transfer. Nat Biomed Eng 4, 421–436

    Not in our library10.1038/s41551-019-0498-9

42. 42.

    Hübner J, Raschke M, Rütschle I (2018 ). Simultaneous evaluation of anti-EGFR-induced tumour and adverse skin effects in a microfluidic human 3D co-culture model. Sci Rep 8, 15010

    Not in our library10.1038/s41598-018-33462-3

43. 43.

    Huh D, Matthews BD, Mammoto A (2010 ). Reconstituting organ-level lung functions on a chip. Science 328, 1662–1668

    Not in our library10.1126/science.1188302

44. 44.

    Huh D, Leslie DC, Matthews BD (2012 ). A human disease model of drug toxicity-induced pulmonary edema in a lung-on-a-chip microdevice. Sci Transl Med 4, 159ra147

    Not in our library10.1126/scitranslmed.3004249

45. 45.

    Hwang TJ, Carpenter D, Lauffenburger JC (2016 ). Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Intern Med 76, 1826–1833

    Not in our library10.1001/jamainternmed.2016.6008

46. 46.

    Ingber DE and Whitesides GM (2012 ). Lab on a chip: United States of America. Lab Chip 12, 2089–2090

    Not in our library10.1039/c2lc90052a

47. 47.

    Jain A, van der Meer AD, Papa AL (2016 ). Assessment of whole blood thrombosis in a microfluidic device lined by fixed human endothelium. Biomed Microdevices 18, 73

    Not in our library10.1007/s10544-016-0095-6

48. 48.

    Jalili-Firoozinezhad S, Gazzaniga FS, Calamari EL (2019 ). A complex human gut microbiome cultured in an an-aerobic intestine-on-a-chip. Nat Biomed Eng 3, 520–531

    Not in our library10.1038/s41551-019-0397-0

49. 49.

    Jang KJ, Otieno MA, Ronxhi J (2019 ). Reproducing human and cross-species drug toxicities using a liver-chip. Sci Transl Med 11, eaax5516

    Not in our library10.1126/scitranslmed.aax5516

50. 50.
    Development of a primary human Small Intestine-on-a-Chip using biopsy-derived organoids · 2018

    No notice
51. 51.

    Kühnlenz J (2019 ). Establishment of a multi-organ-chip based identification platform for endocrine disruptors. Abstracts of the 55th Congress of the European societies of toxicology (EUROTOX 2019) toxicology - Science providing solutions. Toxicol Lett 314, Suppl, 293

    Not in our library10.1016/j.toxlet.2019.09.002

52. 52.

    Leist M, Hasiwa N, Daneshian M (2012 ). Validation and quality control of replacement alternatives – Current status and future challenges. Toxicol Res 1, 8–22

    Not in our library10.1039/c2tx20011b

53. 53.

    Livingston CA, Fabre KM and Tagle DA (2016 ). Facilitating the commercialization and use of organ platforms generated by the microphysiological systems (tissue chip) program through public-private partnerships. Comput Struct Biotechnol J 14, 207–210

    Not in our library10.1016/j.csbj.2016.04.003

54. 54.

    Low LA and Tagle DA (2016 ). Tissue chips to aid drug development and modeling for rare diseases. Expert Opin Orphan Drugs 4, 1113–1121

    Not in our library10.1080/21678707.2016.1244479

55. 55.

    Low LA and Tagle DA (2017a ). Microphysiological systems (“organs-on-chips”) for drug efficacy and toxicity testing. Clin Transl Sci 10, 237–239

    Not in our library10.1111/cts.12444

56. 56.

    Low LA and Tagle DA (2017b ). Organs-on-chips: Progress, challenges, and future directions. Exp Biol Med (Maywood) 242, 1573–1578

    Not in our library10.1177/1535370217700523

57. 57.

    Marx U, Walles H, Hoffmann S (2012 ). ‘Human-on-a-chip’ developments: A translational cutting-edge alternative to systemic safety assessment and efficiency evaluation of substances in laboratory animals and man? Altern Lab Anim 40, 235–257

    Not in our library10.1177/026119291204000504

58. 58.

    Marx U, Andersson TB, Bahinski A (2016 ). Biology-inspired microphysiological system approach to solve the prediction dilemma and substance testing. ALTEX 33, 272–321

    Not in our library10.14573/altex.1603161

59. 59.

    Maschmeyer I, Hasenberg T, Jaenicke A (2015a ). Chip-based human liver-intestine and liver-skin co-cultures- A first step toward systemic repeated dose substance testing in vitro. Eur J Pharm Biopharm 95, 77–87

    Not in our library10.1016/j.ejpb.2015.03.002

60. 60.

    Maschmeyer I, Lorenz AK, Schimek K (2015b ). A four-organ-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents. Lab Chip 15, 2688–2699

    Not in our library10.1039/c5lc00392j

61. 61.

    Mastrangeli M, Millet S, van den Eijnden-van Raaij J (2019a ). Organ-on-chip in development: Towards a roadmap for organs-on-chip. ALTEX 36, 650–668

    Not in our library10.14573/altex.1908271

62. 62.

    Mastrangeli M, Millet S, Mummery C (2019b ). Building blocks for a European organ-on-chip roadmap. ALTEX 36, 481–492

    Not in our library10.14573/altex.1905221

63. 63.

    Materne EM, Ramme AP, Terrasso AP (2015 ). A multi-organ chip co-culture of neurospheres and liver equivalents for long-term substance testing. J Biotechnol 205, 36–46

    Not in our library10.1016/j.jbiotec.2015.02.002

64. 64.

    Miller PG and Shuler ML (2016 ). Design and demonstration of a pumpless 14 compartment microphysiological system. Biotechnol Bioeng 113, 2213–2227

    Not in our library10.1002/bit.25989

65. 65.

    National Academies of Sciences, Engineering, and Medicine, Division of Earth and Life studies, Board on Environmental Studies and Toxicology (2017 ). Using 21st Century Science to Improve Risk-Related Evaluations. Washington, DC, USA: National Academies Press (US).

    Not in our library

66. 66.

    Novak R, Ingram M, Clauson S (2020 ). Robotic fluidic coupling and interrogation of multiple vascularized organ chips. Nat Biomed Eng, Epub ahead of print

    Not in our library10.1038/s41551-019-0497-x

67. 67.

    OECD - Organisation for Economic Co-operation and Development (2005 ). Guidance Document on the Validation and International Acceptance of New or Updated Test Methods for Hazard Assessment OECD Series on Testing and Assessment No. 34 OECD Publishing, Paris https://bit.ly/2EffJp7 (accessed 12.11.2019).

    Not in our library

68. 68.

    OECD (2018 ). Guidance Document on Good In Vitro Method Practices (GIVIMP) Series on Testing and Assessment No. 286 OECD Publishing, Paris

    Not in our library10.1787/9789264304796-en

69. 69.

    Pamies D, Bal-Price A, Simeonov A (2017 ). Good cell culture practice for stem cells and stem-cell-derived models. ALTEX 34, 95–132

    Not in our library10.14573/altex.1607121

70. 70.

    Pamies D, Bal-Price A, Chesné C (2018 ). Advanced good cell culture practice for human primary, stem cell-derived and organoid models as well as microphysiological systems. ALTEX 35, 353–378

    Not in our library10.14573/altex.1710081

71. 71.

    Peel S, Corrigan AM, Ehrhardt B (2019 ). Introducing an automated high content confocal imaging approach for Organs-on-Chips. Lab Chip 19, 410–421

    Not in our library10.1039/c8lc00829a

72. 72.

    Poussin C, Kramer B, Lanz H (2020 ). 3D human microvessel-on-a-chip model for studying monocyte-to-endothelium adhesion under flow - Application in systems toxicology. ALTEX 37, 47–63

    Not in our library10.14573/altex.1811301

73. 73.

    Prantil-Baun R, Nocak R, Das D (2018 ). Physiologically based pharmacokinetic and pharmacodynamic analysis enabled by microfluidically linked organs-on-chips. Annu Rev Pharmacol Toxicol 58, 37–64

    Not in our library10.1146/annurev-pharm-tox-010716-104748

74. 74.

    Ramme AP, Koenig L, Hasenberg T (2019 ). Autologous induced pluripotent stem cell-derived four-organ-chip. Future Sci OA 5, FSO413

    Not in our library10.2144/fsoa-2019-0065

75. 75.

    Sakolish C, Weber EJ, Kelly EJ (2018 ). Technology transfer of the microphysiological systems: A case study of the human proximal tubule tissue chip. Sci Rep 8, 14882

    Not in our library10.1038/s41598-018-33099-2

76. 76.

    Satoh T, Narazaki G, Sugita R (2016 ). A pneumatic pressure-driven multi-throughput microfluidic circulation culture system. Lab Chip 16, 2339–2348

    Not in our library10.1039/c6lc00361c

77. 77.

    Shuler ML (2012 ). Modeling life. Ann Biomed Eng 40, 1399–1407

    Not in our library10.1007/s10439-012-0567-7

78. 78.

    Sieber S, Wirth L, Cavak N (2018 ). Bone marrow-on-a-chip: Long-term culture of human haematopoietic stem cells in a three-dimensional microfluidic environment. J Tissue Eng Regen Med 12, 479–489

    Not in our library10.1002/term.2507

79. 79.

    Sleeboom JFF, Amirabadi HE, Nair P (2018 ). Metastasis in context: Modeling the tumor microenvironment with cancer-on-a-chip approaches. Dis Model Mech 11, dmm033100

    Not in our library10.1242/dmm.033100

80. 80.

    Smirnova L, Kleinstreuer N, Corvi R (2018 ). 3S - Systematic, systemic, and systems biology and toxicology. ALTEX 35, 139–162

    Not in our library10.14573/altex.1804051

81. 81.

    Tagle DA (2019 ). The NIH microphysiological systems program: Developing in vitro tools for safety and efficacy in drug development. Curr Opin Pharmacol 48, 146–154

    Not in our library10.1016/j.coph.2019.09.007

82. 82.
    Membrane-free culture and real-time barrier integrity assessment of perfused intestinal epithelium tubes · 2017

    No notice
83. 83.
    Can Animal Models of Disease Reliably Inform Human Studies? · 2010

    No notice
84. 84.

    van Duinen V, van den Heuvel A, Trietsch SJ (2017 ). 96 perfusable blood vessels to study vascular permeability in vitro. Sci Rep 7, 18071

    Not in our library10.1038/s41598-017-14716-y

85. 85.
    Perfused 3D angiogenic sprouting in a high-throughput in vitro platform · 2018

    No notice
86. 86.

    Vormann MK, Gijzen L, Hutter S (2018 ). Nephrotoxicity and kidney transport assessment on 3D perfused proximal tubules. AAPS J 20, 90

    Not in our library10.1208/s12248-018-0248-z

87. 87.

    Wagner I, Materne EM, Brincker S (2013 ). A dynamic multi-organ-chip for long-term cultivation and substance testing proven by 3D human liver and skin tissue co-culture. Lab Chip 13, 3538–3547

    Not in our library10.1039/c3lc50234a

88. 88.

    Wang G, McCain ML, Yang L (2014 ). Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat Med 20, 616–623.

    Not in our library10.1038/nm.3545

89. 89.

    Waring MJ, Arrowsmith J, Leach AR (2015 ). An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov 14, 475–486

    Not in our library10.1038/nrd4609

90. 90.

    Westein E, van der Meer AD, Kuijpers MJ (2013 ). Atherosclerotic geometries exacerbate pathological throm-bus formation poststenosis in a von Willebrand factor-dependent manner. Proc Natl Acad Sci U S A 110, 1357–1362

    Not in our library10.1073/pnas.1209905110

91. 91.

    Zhang B and Radisic M (2017 ). Organ-on-a-chip devices advance to market. Lab Chip 17, 2395–2420

    Not in our library10.1039/c6lc01554a

Cited by papers we hold 3

• New approach methodologies in human regulatory toxicology – Not if, but how and when! · 2023
  No notice
• Shell microelectrode arrays (MEAs) for brain organoids · 2022
  No notice
• Is it Time for Reviewer 3 to Request Human Organ Chip Experiments Instead of Animal Validation Studies? · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.